Advocates, policy makers, funders and other stakeholders have surfaced a number of questions regarding Descovy (F/TAF) for PrEP – recently approved by the FDA to prevent HIV during anal sex. With Truvada (TDF/FTC) set to go off patent next year, several generic options waiting in the wings, and our community’s reliance on the 340B program for funding PrEP-related services, many have raised concerns about price, policy and programming related to Descovy. Added to the complicated mix of issues are the presence of numerous lawsuits calling into question the safety of Truvada for both treatment and prevention and different PrEP indications for Descovy and Truvada, including different safety profiles. On Monday, November 11, an array of experts helped us sift through the questions – none of which have easy answers, all of which have significant implications for PrEP implementation in the United States.
- Kathie Hiers, CEO of AIDS Alabama
- Amy Killelea, Senior Director, Health Systems & Policy – National Association of State and Territorial AIDS Directors (NASTAD)
- Tim Horn, Director, Medication Access and Pricing – NASTAD
- David Hardy, Immediate-Past Chair, HIV Medicine Association (HIVMA), Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
- Craig Hendrix, Professor of Medicine, Pharmacology, and Epidemiology, Johns Hopkins University School of Medicine.